The benzodiazepine receptor is located close to the GABA receptor in the central nervous system. GABA is a CNS depressant inducing sedation. The binding of an agonist to the benzodiazepine receptor modulates the function of the GABA receptor complex and causes increased activity of GABA [1] [2] [3] .
The ideal antagonist blocks the receptor without exerting effects of its own, and has a longer duration of action than the corresponding agonist. Flumazenil, an imidazo-benzodiazepine [4, 5] , is a pure benzodiazepine antagonist with no major intrinsic activity. Benzodiazepines are used widely as sedatives for diagnostic procedures and in anaesthesia for premedication, induction and maintenance. However, there is frequently an undesirable, prolonged duration of sedativehypnotic actions which persist after termination of surgery. These unwanted effects may be antagonized by administration of flumazenil [6] .
The aims of the present study were to assess the dose of flumazenil required to antagonize the sedative effects of diazepam administered in combination with alfentanil and nitrous oxide for general anaesthesia and to assess the need for postoperative surveillance with an awakeness score after use of flumazenil.
PATIENTS AND METHODS
We studied consecutively 40 adult patients (> 18 yr, ASA groups I-II) undergoing elective surgery for 30 min or more. Patients excluded from the study comprised children, pregnant women and patients receiving chronic treatment with a benzodiazepine equivalent to diazepam 5 mg daily or more. Each patient gave informed consent for the study, which was approved by the local Ethics Committee. The patients were premedicated with diazepam and anaesthetized with diazepam, alfentanil and 66% nitrous oxide in oxygen. For induction, the patients were given alfentanil 0.014 mg kg" 1 i.v. followed by diazepam i.v. injected slowly until loss of the eyelash reflex. The lungs were ventilated with 100 % oxygen, and relaxation was produced with atracurium 0.4 mg kg" were then given flumazenil or placebo i.v. according to a randomized double-blind design. The initial dose was 0.2 mg followed by 0.1 mg min" 1 until the patient was fully awake, or a maximum dosage of 1.0 mg was reached.
At 0, 5, 30, 120 and 240 min after administration of flumazenil, the following assessments were made: (1) State of wakefulness and reaction to pain stimulus, measured on a four-point scale of 0-3 (table I) . (2) Orientation in time and space, and cooperation and motor activity evaluated on a threepoint scale of 0-2 (table I) . (3) Heart rate, arterial pressure and rate of ventilation were recorded. (4) Arterial blood-gas analysis was performed 30 and 120 min after administration of flumazenil.
After 5 min the patients were admitted to the recovery room, supplied with nasal oxygen 4 litre min" 1 and, on feeling pain, were given ketomebidon 1.25-5.0 mg i.m. Ketomebidon (1-[4-(3-hydroxyphenyl)-l-methyl-4-piperidyl]-propan-1-one) is a strong opioid analgesic related structurally to meperidine with pharmacokinetics similar to those of morphine [7] . The patient remained in the recovery room throughout the observation time of 4 h.
Statistics
The two groups were compared by means of the Mann-Whitney/Wilcoxon test for unpaired data. P < 0.05 was taken as significant. Accepting a risk of type II error: P < 0.10 there is a minimum detectable change in awakeness score ^ 3.4.
RESULTS
The two groups were comparable in age, height, doses of drugs administered (excluding flumazenil) and duration of anaesthesia, but not body weight (table II) . Ten patients in each group received supplementary doses of diazepam. There was no difference in the median time from the last supplementary dose of diazepam to end of operation (table II) . The maximum dose given within the last 60 min was diazepam 2.5 mg. The administered dose of flumazenil or placebo was significantly lower in the treatment group, with a median of 0.35 mg, whereas in the placebo group the median was 0.7 mg (P < 0.01) (table II). The wakefulness score before administration of flumazenil (f 0 ) did not differ in the two groups, but 5 min after t 0 patients who received flumazenil were fully awake compared with placebo (P < 0.05) (table III) . This difference was also present at t 30 (30 min after r 0 ), whereas from 120 min after and for the remainder of the observation period the fiumazenil and the placebo group did not differ significantly. Patients receiving fiumazenil were therefore fully awake 5 min after drug administration, and there was no resedation throughout the observation time. In the placebo group, however, patients did not reach this state of wakefulness (score 10) until 120 min (table  III) . There were no intergroup differences in mean arterial pressure (MAP), ventilatory and heart rates, arterial pH, />a c02 , Pa Ol > base excess or oxygen saturation. In both groups there was mild uncompensated metabolic acidosis (table IV) . Nausea was experienced by seven patients in the fiumazenil group, compared with five in the placebo group (P > 0.5). Thirteen patients in the fiumazenil group and 15 in the placebo group received ketomebidon (table II) (P > 0.5).
TABLE III. Sum of wakefulness scores (median (95% confidence limits)). (Maximum possible score = 10)
Time relative to fiumazenil administration 
DISCUSSION
The phase of redistribution of diazepam is short, with a half-life of approximately 0.3 h, but the elimination half-life is as long as 48 h. If it is necessary to antagonize diazepam-induced sedation, there is therefore a risk of resedation. This possibility has been examined mostly by studies of the reversal of benzodiazepine intoxication; in these studies [8] there seems to be a relationship between the dose and type of drug ingested, and the dose of fiumazenil required for antagonism. Kirkegaard and colleagues [9] used fiumazenil for reversal of diazepam sedation in a placebocontrolled study of 40 outpatients undergoing gastroscopy. The patients received diazepam 0.3-0.7 mg kg" 1 and this was antagonized by fiumazenil 0.6-1.0 mg. No resedation occurred within the observation period of 120 min.
Nilsson, Persson and Hartvig [10] performed an open study comparing the antagonism of midazolam sedation after general anaesthesia in combination with alfentanil and nitrous oxide. The patients received a large mean dose of midazolam: approximately 40mg, during 120 min of abdominal surgery; all were antagonized with fiumazenil 1.0 mg. Resedation occurred 1 h after administration of fiumazenil.
In two trials performed by Jensen and colleagues [11] the observation time was 180 min. Fiumazenil was compared with placebo for antagonism of midazolam and diazepam-induced sedation for gastroscopy. Awakening was equally fast in the fiumazenil groups, and no resedation was encountered. Although these data are promising, the observation periods were relatively short in the few studies where flumazenil was used for antagonism of diazepam sedation, after i.v. anaesthesia in combination with opioids, and nitrous oxide.
In one study the observation period was 240 min and resedation was not observed [12] .
We found that flumazenil in a median dose of 0.35 mg was effective in promptly reversing sedation produced by a median dose of diazepam 0.33 mg kg" 1 . In the flumazenil group, patients were maximally awake 5 min after administration of the drug. This corresponds with the findings of other studies [9, 12, 13] , some of which suggested that a dose of flumazenil 0.2 mg should be adequate [14] . Thirty minutes after administration of flumazenil or placebo, we found only a small, although significant, difference in wakefulness scores between the two groups, whereas at 120 min there was no intergroup difference. Resedation did not occur in an observation period of 4h.
Resedation is dependent on the relation between the administered doses of benzodiazepine and flumazenil [3, 5, 8] . The duration of action of flumazenil has been reported to be as short as 30 min [14] .
Flumazenil seems to have only few, insignificant side effects when titrated carefully to a desired response and dose < 1.0 mg [8] . Mild adverse effects have been reported on the EEG, with altered stage 4 sleep with doses > 1.0 mg [15, 16] . More serious adverse effects, which result from benzodiazepine withdrawal, including seizures, have been reported only with doses exceeding 1.0 mg [3, 8, 17] . We did not find any adverse effects that might be ascribed to flumazenil. We had expected to find less respiratory depression in the flumazenil group, but there was no difference in arterial blood-gas data between the two groups. For Pa Oz , P (risk of type II error) was estimated to be > 0.5, and the data are thus inconclusive (probably because of administration of oxygen in the recovery room resulting in a rather large SD-^ 6). For Pa cc , 2 , P was less than 0.10. There was no difference between the groups in rate of ventilation, arterial pressure or blood-gas data (P < 0.10 in all cases).
